Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Account Payables: 2014-2025

Historic Change in Account Payables for Fennec Pharmaceuticals (FENC) over the last 11 years, with Sep 2025 value amounting to -$75,000.

  • Fennec Pharmaceuticals' Change in Account Payables rose 87.07% to -$75,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 115.87%. This contributed to the annual value of -$537,000 for FY2024, which is 138.69% down from last year.
  • Per Fennec Pharmaceuticals' latest filing, its Change in Account Payables stood at -$75,000 for Q3 2025, which was down 111.35% from $661,000 recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Change in Account Payables ranged from a high of $2.0 million in Q1 2025 and a low of -$1.8 million during Q2 2021.
  • Its 3-year average for Change in Account Payables is $316,000, with a median of $58,000 in 2023.
  • In the last 5 years, Fennec Pharmaceuticals' Change in Account Payables surged by 1,387.30% in 2021 and then slumped by 1,405.17% in 2024.
  • Over the past 5 years, Fennec Pharmaceuticals' Change in Account Payables (Quarterly) stood at $477,000 in 2021, then slumped by 52.29% to -$144,000 in 2022, then skyrocketed by 681.25% to $837,000 in 2023, then plummeted by 174.79% to -$626,000 in 2024, then soared by 87.07% to -$75,000 in 2025.
  • Its Change in Account Payables stands at -$75,000 for Q3 2025, versus $661,000 for Q2 2025 and $2.0 million for Q1 2025.